Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms
Precision Clinical Medicine · 13.10.2025 · 8 (4)
DOI: 10.1093/pcmedi/pbaf031 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Precision Clinical Medicine, online erschienen am 14.11.2025. Verfasst von Anzhu Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hosp…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project, National Natural Science Foundation of China, Central High-level Hospital of Traditional Chinese Medicine.
Abstract (Originalsprache)
Background
Shenzhuo Formula (SZF), a modified Didang Tang, is used for diabetic kidney disease (DKD), though high-quality evidence is limited.
Methods
In a randomized, double-blind, double-dummy, active-controlled, multicenter trial, irbesartan (IRB) was the control. A Bayesian model assessed efficacy. Mechanistic studies included Olink inflammation proteomics, single-cell RNA sequencing (scRNA-seq) of KK-Ay mouse kidneys, and in vivo experiments.
Results
A total of 120 DKD patients with macroalbuminuria were randomized (SZF n = 57, IRB n = 63). At 24 weeks, 24 h urinary total protein change was −0.03 (−0.24 to 0.18) g/24 h in the SZF group and 0.08 (−0.30 to 0.14) g/24 h in the IRB group (P = 0.61). Estimated glomerular filtration rate improved with SZF by 5.91 (1.80 to 10.01) mL/min/1.73m² but declined with IRB by −1.67 (−5.18 to 1.84) mL/min/1.73m² (P < 0.01). Serum creatinine decreased with SZF by −5.15 (−9.73 to −0.56) μmol/L but increased with IRB by 3.39 (−0.84 to 7.61) μmol/L (P < 0.01). Traditional Chinese medicine syndrome response was higher with SZF (89.47% vs. 63.49%, P < 0.01). Safety and metabolic parameters were comparable. Bayesian analysis favored SZF for renal benefit. Mechanistically, SZF downregulated CX3CL1 in endothelial cells and MCP-1 in mesangial and tubular cells, suggesting anti-inflammatory effects restoring endothelial function and attenuating fibrosis.
Conclusions
SZF matched IRB in proteinuria reduction but was superior in preserving renal function and improving traditional Chinese medicine symptoms in DKD, with good safety. Benefits may involve suppression of CX3CL1/MCP-1-mediated inflammation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Ch…
- Metabolic Disease Institute, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
- Department of Endocrinology, Beijng Hepingli Hospital, Beijing 100013, China.
- Baoding Traditional Chinese Medicine Hospital, Baoding 071000, China.
- Shijiazhuang Traditional Chinese Medicine Hospital, Shijiazhuang 050051, China.
- Zouping Country Hospital of Traditional Chinese Medicine, Zouping 256200, China.
Förderung
- National Science and Technology Major Project
- National Natural Science Foundation of China
- Central High-level Hospital of Traditional Chinese Medicine
Zitieren
APA
Wang, A., Huang, Y., Wei, Y., Zhang, L., Chen, H., Wang, X., Cui, Z., Wang, B., Liu, W., Chen, C., Lei, Y., Zheng, Z., Wei, Y., Mi, J., Lu, K., Zhang, Y., Tong, X., & Zhao, L. (2025). Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms. Precision Clinical Medicine, 8(4). https://doi.org/10.1093/pcmedi/pbaf031
Vancouver
Wang A, Huang Y, Wei Y, Zhang L, Chen H, Wang X, et al. Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms. Precision Clinical Medicine. 2025;8(4). doi:10.1093/pcmedi/pbaf031
BibTeX
@article{Wang2025,
author = {Wang, Anzhu and Huang, Yishan and Wei, Yu and Zhang, Lili and Chen, Hongdong and Wang, Xiaoqing and Cui, Zhimei and Wang, Bin and Liu, Wei and Chen, Chao and Lei, Ye and Zheng, Zhonghua and Wei, Yan and Mi, Jia and Lu, Keda and Zhang, Ying and Tong, Xiaolin and Zhao, Linhua},
title = {Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms},
journal = {Precision Clinical Medicine},
year = {2025},
volume = {8},
number = {4},
doi = {10.1093/pcmedi/pbaf031}
}
EUVIMED